Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, b

Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corte

Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock

Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's afte

Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analy

Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

WD-40 Co (WDFC) shares rise sharply in pre-market trading after reporting better-than-expected thir

Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventor

The Company expects REZENOPY™ to become commercially available for purchase in August. The Company i

The Company recently secured additional payor coverage representing approximately 12.5 million incre

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for m

5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO Marke

Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analy

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension fo

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a s

https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and plan

Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded hea

Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US instit

Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ:SCNX) with a Buy

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical op